ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1888

SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015

Eric Yen and Ram R. Singh, UCLA, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: death, Lupus, morbidity and mortality and outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: 4M094 ACR/ARHP Abstract: Health Services Research I: Focus on Big Data (1887–1892)

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Ten-year survival of SLE has improved from <50% in the 1950s to ~95% in the 2000s. However, the relative and true disease burden for SLE is not understood. Disease burden can be measured using a variety of indicators such as mortality, morbidity or financial cost. A recent analysis of 62,843 SLE deaths from the Centers for Disease Control (CDC)’s mortality database showed that the age-standardized mortality rate for SLE remains high relative to general population mortality rate. However, mortality rates may not adequately measure SLE burden, because among those who died, a fifth of SLE patients died before reaching 40 years of age. Premature mortality is an important way to quantify disease burden. In constructing a measure of premature death, an arbitrary limit to life is chosen, and the calculation of the difference between an age at death and this arbitrary limit is defined as the life lost as a result of that death. Here, we measured the years of potential life lost (YPLL) for SLE relative to CDC’s top 15 leading causes of death and to 12 other autoimmune diseases.

Methods: This is a population-based study. Death counts were obtained from the CDC-WONDER database. Number of deaths between January 1, 2000 and December 31, 2015 were tabulated for 28 diseases, including SLE, top 15 CDC’s leading causes-of-death, and 12 other autoimmune diseases. To calculate YPLL, each decedent’s age at death from a specific disease was subtracted from a predetermined age of 75 years. The years of potential life lost were then added together to yield the total YPLL.

Results: SLE was recorded as the underlying or a contributing cause of death in 28,411 women from 2000 to 2015. The ranking of SLE deaths relative to the CDC’s official leading-causes-of-death list in females showed that SLE is within the top 15 leading causes-of-death in reproductive age women (15-44 years) and tenth among women ages 15-24 years. Hence, we calculated YPLL for SLE relative to the top 15 leading causes-of-death in women ages 15-44 and 15-24 years. YPLL for SLE was 304.2 thousand years in women ages 15-44 and 66.2 thousand years in women ages 15-24. SLE-YPLL ranked 14th in women ages 15-44 and 8th in women ages 15-24 above diabetes mellitus, HIV disease, septicemia, chronic lower respiratory disease, anemias, nephritis, and cerebrovascular disease. Among autoimmune diseases, SLE ranked #2 above insulin-dependent diabetes mellitus, myocarditis, multiple sclerosis, systemic sclerosis, rheumatoid arthritis, Addison’s disease, dermatomyositis, chronic active hepatitis, myasthenia gravis, primary biliary cirrhosis, and autoimmune hemolytic anemia in women ages 15-44 years. SLE ranked #1 autoimmune disease cause of YPLL in women ages 15-24 years.

Conclusion: SLE is among the leading causes of YPLL in young women, underscoring SLE as an important public health issue. SLE ranked #1 leading autoimmune disease cause of YPLL in women ages 15-24. These data warrant further studies on SLE disease burden, which can be used to develop and prioritize public health programs, assess performance of changes in SLE management, identify high-risk populations, and set research priorities and funding, which may eventually reduce SLE burden.


Disclosure: E. Yen, None; R. R. Singh, None.

To cite this abstract in AMA style:

Yen E, Singh RR. SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015 [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/sle-among-the-leading-causes-of-years-of-potential-life-lost-in-young-women-population-based-study-2000-2015/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sle-among-the-leading-causes-of-years-of-potential-life-lost-in-young-women-population-based-study-2000-2015/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology